What 22 Analyst Ratings Have To Say About Edwards Lifesciences
Portfolio Pulse from Benzinga Insights
Over the past three months, 22 analysts have shared their insights on Edwards Lifesciences (NYSE:EW), with a mix of bullish and bearish opinions. The average 12-month price target has decreased by 11.29% to $87.23. Analysts have recently lowered their price targets, reflecting a negative shift in sentiment.
July 29, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have shown a negative shift in sentiment towards Edwards Lifesciences, lowering the average 12-month price target by 11.29% to $87.23. This reflects concerns over the company's recent revenue decline and overall market performance.
The decrease in the average price target by 11.29% and the lowering of ratings by multiple analysts indicate a negative outlook for Edwards Lifesciences. This is likely due to the company's recent revenue decline and underperformance compared to industry peers.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100